Phase I safety and antigenicity of TA-GW: a recombinant HPV6 L2E7 vaccine for the treatment of genital warts

199967 citationsJournal Article

Authors

Good health and well-being

Published in: Vaccine

Volume 17, Issue 1, pp. 40-49

Field-Weighted Citation Impact: 4.66